In August 2018, LivaNova PLC launched a global registry to evaluate the use of its Vagus Nerve Stimulation Therapy® (VNS Therapy) System for patients with drug-resistant epilepsy.
The system consists of two implantable components: a programmable electronic pulse generator that is connected to a bipolar electrical lead, which sends mild pulses to stimulate the vagus nerve at regular intervals throughout the day.
This study will enroll up to 2,000 patients and follow them for five years. The analysis of the data from this large repository will help to evaluate the safety and effectiveness of this therapy, as well as clinical outcomes for patients.
The Oxford Epilepsy Research Group, led by Arjune Sen, enrolled the first patient in Europe to the trial, and has recruited the largest number of patients to the study so far, along with Child Neurology Consultants Austin, Dr Keough.
Child Neurology Consultants Austin, Dr. Keough